AXIOMATIC-SSP: Cautious Optimism on Factor XI Inhibitor in Stroke
The new factor XI inhibitor antithrombotic, milvexian, showed promising results in a dose-finding phase 2 trial in patients with acute ischemic stroke or TIA, on top of dual antiplatelet therapy.
Medscape Medical News
source https://www.medscape.com/viewarticle/979860?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/979860?src=rss
Comments
Post a Comment